Evaluation Of A Novel Connexin-Based Peptide For The Treatment Of Diabetic Wounds

新型连接蛋白肽治疗糖尿病伤口的评价

• 批准号: 8046461
• 负责人: Gautam Sudhir Ghatnekar
• 金额: $ 32.37万
• 依托单位: XEQUEL BIO, INC.
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-09-15 至 2012-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8046461
• 关键词: Acute; Advanced Development; Adverse reactions; American; Amputation; Animals; Appearance; Autopsy; Becaplermin; Binding; Biomedical Engineering; Blood Vessels; Cells; Chronic; Clinical; Clinical Research; Clinical Trials; Comparative Study; Connexin 43; Connexins; Cost Savings; Development; Diabetes Mellitus; Diabetic Foot; Diabetic Foot Ulcer; Diabetic wound; Disease; Evaluation; Extravasation; Eye; Family member; Family suidae; Fibrosis; Foot Ulcer; Funding; Future; Gangrene; Gel; Genes; Granulation Tissue; Growth; Healed; Healthcare; Healthcare Systems; Heart Diseases; Hospitalization; Human; Immune; Impaired wound healing; In Situ Hybridization; Infection; Inflammation; Inflammatory; Injury; Investigational Drugs; Laboratory Research; Market Research; Measures; Mechanics; Medical center; Modeling; New Drug Approvals; Operative Surgical Procedures; Oryctolagus cuniculus; Patients; Pattern; Peptides; Pharmaceutical Preparations; Pharmacologic Substance; Pharmacotherapy; Phase; Plastic Surgical Procedures; Play; Proteins; Quality of life; Rattus; Redness; Research; Rodent; Role; Safety; Signal Pathway; Signal Transduction; Skin; Small Business Innovation Research Grant; Solutions; South Carolina; Technology; Time; Topical application; Toxic effect; Toxicokinetics; Ulcer; United States; Universities; Walking; Wound Healing; base; cost; db/db mouse; design; diabetic; diabetic patient; diabetic wound healing; efficacy evaluation; foot; good laboratory practice; healing; improved; insight; interest; intravenous administration; irritation; loved ones; man; middle age; mouse model; neutrophil; novel; pharmacokinetic characteristic; phase 2 study; pre-clinical; public health relevance; research and development; response; skin regeneration; treatment strategy; wound

DESCRIPTION (provided by applicant): According to the American Diabetes Association, there are more than 16 million people in the United States with known diabetes. Diabetic patients commonly demonstrate impaired wound healing. Approximately 20 percent of patients with diabetes will develop foot ulceration in their lifetime. Diabetic foot ulceration (DFU) represents a major problem that can significantly impair the patient's quality of life, require prolonged hospitalization, and may involve infection, gangrene, and amputation. It has been estimated that for each new foot ulcer the attributable cost for a middle-aged diabetic man in the first two years is approximately $ 30,000. The cost of DFU to the healthcare system is over one billion dollars per year in the United States. A well- established reason as to why diabetic wounds are tough to heal is that they do not progress through the normal healing phases. Instead, it is thought that diabetic wounds are caught and remain trapped in the initial inflammatory phase of wound healing. FirstString Research, Inc. (FSR) is a biotech company located in Charleston, South Carolina. The founders of FSR, Drs. Robert Gourdie and Gautam Ghatnekar are co inventors of a class of novel bioengineered peptides - we refer to as ACT peptides. Phase I funded studies in the diabetic C57BL/KsJ-m+/+Leptdb (db+/db+) mouse model have provided strong evidence for efficacy and potential of the ACT1 peptide in the treatment of diabetic wounds. The peptide effects a significantly faster closure rate. Subjective parameters such as redness and overall appearance were also substantially improved in ACT1 treated wounds. ACT1 peptide did not show any adverse reactions or safety concerns in our Phase I SBIR studies, as evaluated by a complete necropsy and histopathological evaluation. Moreover, to enhance our ability to understand and anticipate issues associated with the safety and efficacy of ACT1peptide, we will also use gene microarray and computational approaches to analyze effects on key signaling pathways involved in wound healing. Of particular interest will be changes induced in angiogenic signaling that provide basic mechanistic insight into the regeneration of skin vascular pattern in wounds treated with ACT1 peptide. Our market research has indicated that present therapies and drugs for wound healing in diabetes and chronic wounds in general are predominantly symptomatic, empirical, unpredictable, and largely ineffective. Our ACT1 peptide potentially offers a mechanistically based solution to not just faster wound closure but also significant cost savings and more importantly improving the quality of life in diabetic patients. In this Phase II application, Dr. Paul Ehrlich, Director for the Wound Healing Research Laboratory in the Division of Plastic Surgery, Department of Surgery, Hershey Medical Center at Penn State University and Dr. Indu Parikh, President and CSO, BioMarck Pharmaceuticals, Durham, NC have agreed to assist us in achieving our aims. PUBLIC HEALTH RELEVANCE: Diabetes is a debilitating condition that threatens the quality of life of not just the people suffering from the disease but also family members and loved ones. Approximately 20 percent of patients with diabetes develop foot ulceration in their lifetime and they demonstrate impaired wound healing. A well-accepted reason for the poor healing of the diabetic or chronic wounds in general is that they are 'stuck' in the inflammatory phase. This technology provides promise for reduced inflammation and faster healing of diabetic wounds thereby improving the quality of life and saving millions of dollars in health care related costs.

描述(申请人提供)：根据美国糖尿病协会的数据，美国有1600多万人患有已知的糖尿病。糖尿病患者通常表现为伤口愈合受损。大约20%的糖尿病患者在他们的一生中会发展成足部溃疡。糖尿病足溃疡(DFU)是一个严重损害患者生活质量的主要问题，需要长期住院，并可能涉及感染、坏疽和截肢。据估计，一个中年糖尿病男性在头两年的每一个新的足部溃疡的可归因性成本约为30,000美元。在美国，DFU每年给医疗系统造成的成本超过10亿美元。糖尿病伤口很难愈合的一个公认的原因是，它们不会在正常的愈合阶段取得进展。相反，人们认为糖尿病伤口会被捕获，并停留在伤口愈合的初始炎症阶段。FirstString Research，Inc.(FSR)是一家位于南卡罗来纳州查尔斯顿的生物技术公司。FSR的创始人Robert Gourdie博士和Gautam Ghatnekar博士是一类新型生物工程多肽的共同发明者，我们称之为ACT多肽。在糖尿病C57BL/KSJ-m+/+Leptdb(db+/db+)小鼠模型上进行的I期资助研究为ACT1肽治疗糖尿病伤口的有效性和潜力提供了强有力的证据。这种多肽显著加快了闭合率。在ACT1治疗的伤口中，诸如发红和整体外观等主观参数也得到了显著改善。在我们的I期SBIR研究中，Act1肽没有显示任何不良反应或安全性问题，这是通过全面的尸检和组织病理学评估进行的。此外，为了增强我们理解和预测与ACT1肽的安全性和有效性相关的问题的能力，我们还将使用基因微阵列和计算方法来分析参与伤口愈合的关键信号通路的影响。尤其令人感兴趣的是血管生成信号的变化，这些变化为用ACT1肽治疗的伤口中皮肤血管模式的再生提供了基本的机制洞察。我们的市场研究表明，目前用于糖尿病和慢性伤口愈合的治疗方法和药物主要是有症状的、经验性的、不可预测的，而且基本上无效。我们的ACT1肽潜在地提供了一种基于机械的解决方案，不仅可以更快地闭合伤口，还可以显著节省成本，更重要的是提高糖尿病患者的生活质量。在第二阶段申请中，宾夕法尼亚州立大学好时医学中心整形外科创伤愈合研究实验室主任Paul Ehrlich博士和北卡罗来纳州达勒姆BioMarck制药公司总裁兼CSO Indu Parikh博士已同意协助我们实现我们的目标。 与公共卫生相关：糖尿病是一种衰弱的疾病，不仅威胁到疾病患者的生活质量，还威胁到家庭成员和亲人的生活质量。大约20%的糖尿病患者在他们的一生中发展为足部溃疡，他们表现出伤口愈合受损。糖尿病或慢性创面普遍愈合不良的一个公认的原因是，它们处于发炎阶段。这项技术有望减少炎症，加快糖尿病伤口的愈合，从而提高生活质量，并节省数百万美元的医疗保健相关成本。